PHGE BiomX Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

PHGE [AMEX]

BiomX Inc.

Healthcare | Drug Manufacturers - Specialty & Generic | Israel

statements

Index	-	P/E	-	EPS (ttm)	-4.05	Insider Own	3.60%	Shs Outstand	22.90M	Perf Week	7.24%
Market Cap	120.09M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	18.18M	Perf Month	5.23%
Income	-26.70M	PEG	-	EPS next Q	-	Inst Own	26.30%	Short Float	0.19%	Perf Quarter	-19.46%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-0.09%	Short Ratio	1.04	Perf Half Y	-43.87%
Book/sh	3.45	P/B	1.63	EPS next Y	-	ROA	-	Target Price	-	Perf Year	-42.49%
Cash/sh	3.53	P/C	1.59	EPS next 5Y	-	ROE	-	52W Range	4.52 - 11.50	Perf YTD	-41.87%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-33.88%	Beta	-
Dividend %	-	Quick Ratio	18.90	Sales past 5Y	-	Gross Margin	-	52W Low	68.22%	ATR	0.30
Employees	73	Current Ratio	18.90	Sales Q/Q	-	Oper. Margin	-	RSI (14)	74.70	Volatility	6.53% 5.02%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-303.00%	Profit Margin	-	Rel Volume	17.93	Prev Close	5.63
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 13 BMO	Payout	-	Avg Volume	33.69K	Price	7.60
Recom	-	SMA20	39.52%	SMA50	36.88%	SMA200	0.80%	Volume	152,338	Change	35.06%

Aug-06-20 07:00AM	BiomX to Report Second Quarter 2020 Financial Results on Aug. 13, 2020 Business Wire
May-14-20 06:30AM	BiomX Reports First Quarter 2020 Financial Results and Provides Business Update Business Wire -8.48%
May-11-20 05:00PM	BiomX to Announce First Quarter 2020 Financial Results on May 14, 2020 Business Wire
Apr-07-20 04:05PM	BiomX Announces Date of 2020 Annual Meeting of Stockholders Business Wire -11.28%
Mar-31-20 06:30AM	BiomX Announces Positive Topline Data from Phase 1 Study for Lead Candidate BX001 for Acne-Prone Skin Business Wire -9.33%
Mar-26-20 06:30AM	BiomX Reports Full Year 2019 Financial Results and Provides Business Update Business Wire +7.45%
Mar-20-20 08:00AM	BiomX Discloses Acne Pre-clinical Data Planned for 2020 AAD Annual Meeting Business Wire
Feb-17-20 07:00AM	BiomX To Present Pre-clinical Data at the Plenary Session of the AACR Microbiome, Viruses, and Cancer Conference Business Wire
Dec-02-19 07:30AM	BiomX Announces Completion of Enrollment for Double-Blind, Placebo-Controlled Clinical Study of BX001 in Acne-Prone Skin Business Wire
Nov-12-19 07:30AM	BiomX Presents Preclinical Results of its Phage Therapy Program Targeting Primary Sclerosing Cholangitis Business Wire -5.53%
07:25AM	Stone Street Group Initiates Coverage On BiomX Inc. PR Newswire
Nov-04-19 05:38PM	BiomX Appoints Russell G. Greig, Ph.D, as Chairman of the Board of Directors and Lynne Sullivan as Board Director Business Wire
07:30AM	BiomX To Present at Plenary Session of the AASLD Liver Conference Business Wire

BiomX Inc., a clinical stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), liver, primary sclerosing cholangitis, and cancer. The company's lead product candidate BX001, which is in phase I that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type; BX002, a therapeutic phage product to treat IBD; BX003, targets bacteria associated with progressive liver disorder (PSC), a rare inflammatory liver disease; and CRC, targets strains of bacteria found in colorectal cancer tumors. The company has license agreement collaboration with The Weizmann Institute of Science to develop, test, manufacture, produce, and sell microbiome-based therapeutic product candidate; Takeda, develops formulations for phage therapy manufacturing intermediates and for the final form to be administered; Keio University and JSR Corporation, a set of bacterial targets for the development and commercialization of phage therapies to treat IBD; and Janssen Research & Development, LLC to utilize XMarker microbiome-based biomarker discovery platform. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chimovits Erez	Director	Dec 19	Buy	8.90	3,500	31,150	2,313,489	Dec 20 01:56 PM
OrbiMed Israel BioFund GP Limi	Director	Dec 19	Buy	8.90	3,500	31,150	2,313,489	Dec 20 01:58 PM
OrbiMed Israel BioFund GP Limi	Director	Dec 18	Buy	8.93	500	4,465	2,309,989	Dec 20 01:58 PM
Chimovits Erez	Director	Dec 18	Buy	8.93	500	4,465	2,309,989	Dec 20 01:56 PM
OrbiMed Israel BioFund GP Limi	Director	Dec 11	Buy	8.92	5,400	48,168	2,309,489	Dec 12 06:52 PM
Chimovits Erez	Director	Dec 11	Buy	8.92	5,400	48,168	2,309,489	Dec 12 06:54 PM
Chimovits Erez	Director	Dec 10	Buy	8.75	3,400	29,750	2,304,089	Dec 12 06:54 PM
OrbiMed Israel BioFund GP Limi	Director	Dec 10	Buy	8.75	3,400	29,750	2,304,089	Dec 12 06:52 PM
OrbiMed Israel BioFund GP Limi	Director	Dec 09	Buy	8.68	6,000	52,080	2,300,689	Dec 09 08:30 PM
Chimovits Erez	Director	Dec 09	Buy	8.68	6,000	52,080	2,300,689	Dec 09 08:19 PM
Chimovits Erez	Director	Dec 06	Buy	8.00	800	6,400	2,294,689	Dec 09 08:19 PM
OrbiMed Israel BioFund GP Limi	Director	Dec 06	Buy	8.00	800	6,400	2,294,689	Dec 09 08:30 PM
OrbiMed Israel BioFund GP Limi	Director	Dec 05	Buy	7.99	3,400	27,166	2,293,889	Dec 09 08:30 PM
Chimovits Erez	Director	Dec 05	Buy	7.99	3,400	27,166	2,293,889	Dec 09 08:19 PM
GROSSMAN JONAS	Director	Nov 20	Buy	8.00	1,400	11,206	6,500	Nov 20 04:32 PM
GROSSMAN JONAS	Director	Nov 19	Buy	7.57	4,100	31,049	5,100	Nov 20 04:32 PM
GROSSMAN JONAS	Director	Nov 18	Buy	6.99	1,000	6,989	1,000	Nov 20 04:32 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience